enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Senile osteoporosis - Wikipedia

   en.wikipedia.org/wiki/Senile_osteoporosis

   Primary, or involuntary osteoporosis, can further be classified into Type I or Type II. [1] Type I refers to postmenopausal osteoporosis and is caused by the deficiency of estrogen. [1] While senile osteoporosis is categorized as an involuntary, Type II, and primary osteoporosis, which affects both men and women over the age of 70 years.

3. Romosozumab - Wikipedia

   en.wikipedia.org/wiki/Romosozumab

   Romosozumab, sold under the brand name Evenity (/ ɪ ˈ v ɛ n ɪ t i / ih-VENN-ih-tee or with the pin-pen merger, / ɪ ˈ v ɪ n ɪ t i / ih-VINN-ih-tee), is a medication used to treat osteoporosis. [7] [8] It has been found to decrease the risk of fractures of the spine. [7] Common side effects include headache, joint pain, and injection site ...

4. Denosumab - Wikipedia

   en.wikipedia.org/wiki/Denosumab

   In December 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Stoboclo, intended for the treatment of osteoporosis in women who have been through menopause, bone loss linked to hormone ablation in men at increased risk of fractures and bone loss associated with long-term ...

5. First osteoporosis drug of its kind for more than a decade ...

   www.aol.com/first-osteoporosis-drug-kind-more...

   The drug is one of only two treatments that help to promote bone formation, and the first to reduce bone loss at the same time. First osteoporosis drug of its kind for more than a decade approved ...

6. 24 Things You Really to Know About Osteoporosis ... - AOL

   www.aol.com/24-things-really-know-osteoporosis...

   Osteoporosis affects more women than men. Of the estimated 10 million Americans with osteoporosis, more than 8 million (or 80%) are women. Women are more likely to get osteoporosis because:

7. Merck Announces Osteoporosis Drug Success - AOL

   www.aol.com/2012/10/15/merck-announces-new-drug...

   Pharmaceutical giant Merck (NYS: MRK) reported promising results from a phase II drug trial for its new osteoporosis drug, odanacatib. Merck plans to submit applications for the drug to U.S ...